• 综述 • 上一篇
CHEN Mei-jie;CHEN Song;YIN Ya-fu;LI Ya-ming
［1］Wahl R L, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors［J］. Journal of Nuclear Medicine, 2009, 50 Suppl 1(2): 122S-150S.
［2］Huang W, Zhou T, Ma L, et al. Standard uptake value and metabolic tumor volume of 18F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced nonsmall cell lung cancer［J］. European Journal of Nuclear Medicine and Molecular Imaging,2011, 38(9): 1628-1635.
［3］Novello S, Vavalà T, Levra M G, et al. Early response to chemotherapy in patients with non-small-cell lung cancer assessed by ［18F］-Fluoro-Deoxy-D-Glucose positron emission tomography and computed tomography［J］. Clinical Lung Cancer,2013, 14(3): 230-237.
［4］Roedl J B, Colen R R, Holalkere N S, et al. Adenocarcinomas of the esophagus: Response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT comparison to histopathologic and clinical response evaluation［J］. Radiotherapy and Oncology, 2008, 89(3): 278-286.
［5］Kidd E A, Thomas M, Siegel B A, et al. Changes in cervical cancer FDG uptake during chemoradiation and association with response［J］. International Journal of Radiation Oncology Biology Physics,2013, 85(1): 116-122.
［6］Yanagawa M, Tatsumi M, Miyata H, et al. Evaluation of response to neoadjuvant chemotherapy for esophageal cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors［J］. Journal of Nuclear Medicine, 2012, 53(6): 872-880.
［7］Swisher S G, Maish M, Erasmus J J. Utility of PET/ CT and EUS to jdentify pathologic responders in esophageal cancer［J］. Annals Thoracic Surgery,2004, 78(78): 1152-1160.
［8］Ott K, Weber W A, Lordick F, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction［J］. Journal of Clinical Oncology, 2006, 24(29): 4692-4698.
［9］de Geus-Oei L F, van H F, Visser E P, et al. Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer［J］. Journal of Nuclear Medicine,2007, 48(10): 1592-1598.
［10］Nahmias C, Hanna W T, Wahl L M, et al. Time course of early response to chemotherapy in non-small cell lung cancer patients with 18F-FDG -PET/CT［J］. Journal of Nuclear Medicine, 2007, 48(5): 744-751.
［11］Weber W A, Petersen V, Schmidt B, et al. Positron emission tomography in nonsmall cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use［J］. Journal of Clinical Oncology,2003, 21(14): 2651-2657.
［12］Francis R J, Byrne M J, van A A, et al. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans［J］. Journal of Nuclear Medicine,2007, 48(9): 1449-1458.
［13］Janssen M H M, llers M C, Riedl R G, et al. Accurate prediction of pathological rectal tumor response after two weeks of preoperative radiochemotherapy using (18)F-fluorodeoxyglucose-positron emission Tomography-computed Tomography Imaging［J］. International Journal of Radiation Oncology Biology Physics,2010, 77(2): 392-399.
［14］Dutour A, Decouvelaere A V, Monteil J, et al. 18F-FDG PET SUVmax correlates with osteosarcoma histologic response to neoadjuvant chemotherapy: preclinical evaluation in an orthotopic rat model［J］. Journal of Nuclear Medicine, 2009, 50(9): 1533-1540.
［15］Dose S J, Bader M, Jenicke L, et al. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET［J］. Journal of Nuclear Medicine,2005, 46(7): 1144-1150.
［16］Zhu W, Xing L, Yue J, et al. Prognostic significance of SUV on PET/CT in patients with localized oesophagogastric junction cancer receiving neoadjuvant chemotherapy/chemoradiation: a systematic review and meta analysis［J］. The British Journal of Radiology, 2012, 85(1017): e694-e701.
［17］Kaira K, Endo M, Asakura K, et al. Ratio of standardized uptake value on PET helps predict response and outcome after chemotherapy in advanced non-small cell lung cancer［J］. Annal of Nuclear Medicine,2010, 24(10): 697-705.
［18］Na I I, Byun B H, Kang H J, et al.18F-fluoro-2-deoxy-glucose uptake predicts clinical outcome in patients with gefitinib treated non-small cell lung cancer［J］. linical Cancer Research, 2008, 14(7): 2036-2041.
［19］Yamamoto M, Tsujikawa T, Fujita Y, et al. Metabolic tumor burden predicts prognosis of ovarian cancer patients who receive platinum-based adjuvant chemotherapy［J］. Cancer Science, 2016: 107(4): 478-485.
［20］Heijmen L, ter Voert E E, Oyen W J, et al. Multimodality imaging to predict response to systemic treatment in patients with advanced colorectal cancer［J］. PLoS One, 2015: 10(4): e0120823.
［21］Kiyohara S, Nagamachi S, Wakamatsu H, et al. Usefulness of metabolic volume and total lesion glycolysis for predicting therapeutic response in cancer therapy by 18F-FDG PET/CT［J］. The Japanese Journal of Nulear Medicine,2010, 47(4): 453-461.
［22］Cook G J R, Yip C, Siddique M, et al. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?［J］. Journal of Nuclear Medicine,2013, 54(1): 19-26.
［23］Guillem J G, Ruby J A, Leibold T, et al. Neither FDG-PET nor CT can distinguish between a pathological complete response and an incomplete response after neoadjuvant chemoradiation in locally advanced rectal cancer: a prospective study［J］. Annals of Surgery, 2013, 258(2): 289-295.
［24］Lee P, Bazan J G, Lavori P W, et al. Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non-small-cell lung cancer［J］. Clinical Lung Cancer, 2011, 13(1): 52-58.
［25］Fonti R, Larobina M, Del Vecchio S,et al. Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma［J］. Journal of Nuclear Medicine,2012, 53(12): 1829-1835.
［26］Zhang H, Wroblewski K, Liao S, et al. Prognostic value of metabolic tumor burden from 18F-FDG PET in surgical patients with nonesmall-cell lung cancer［J］. Academic Radiology,2013, 20: 32-40.
［27］Manohar K, Mittal B R, Bhattacharya A, et al. Prognostic value of quantitative parameters derived on initial staging 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with high-grade non-hodgkin’s lymphoma［J］. Nuclear Medicine Communications, 2012, 33(9): 974-981.
［28］Liu J, Dong M, Sun X, et al.Prognostic value of 18F-FDG PET/CT in surgical non-small cell lung cancer: a meta-analysis［J］. PLoS One,2016,11(1): e0146195.
［29］Bazan J G, Koong A C, Kapp D S, et al. Metabolic tumor volume predicts disease progression and survival in patients with squamous cell carcinoma of the anal canal［J］. Journal of Nuclear Medicne,2013, 54(1): 27-32.
|No related articles found!|